Trial Profile
A Phase 4, Observational Study to Explore How Different Treatment Regimens Affect Continuation With Treatment in the First 6 Months Following Initiation of XAGRID Into Adult Patients' Essential Thrombocythemia Therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Anagrelide (Primary)
- Indications Essential thrombocythaemia
- Focus Therapeutic Use
- Sponsors Shire
- 27 Nov 2015 New trial record